Drugs / sintilizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04401813 | Jun 2020 → Jun 2024 | hepatocellular carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sintilizumab | “Received IBI310 combined with sintilizumab 200mg” NCT04401813 ↗ |